Low-grade gliomas

Current Treatment Options in Oncology

Volumn 10, Issue 3-4, 2009, Pages 231-242

  Ruiz, Jimmy ^a   Lesser, Glenn J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; EVEROLIMUS; IMATINIB; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME;

ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOME MAPPING; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 70350294669     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-009-0096-2     Document Type: Review

References (57)

1. Kleihues P: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000
2. Central Brain Tumor Registry of the United States 2004: Primary Brain Tumors in the United States, 1997-2001, 2004
3. Claus EB, Black PM: Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001. Cancer 2006, 106:1358-1363. doi: 10.1002/cncr.21733.
4. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005, 64:479-489.
5. Pouratian N, Mut M, Jagannathan J, Lopes MB, Shaffrey ME, Schiff D: Low-grade gliomas in older patients: A retrospective analysis of prognostic factors. J Neurooncol. 2008, 90:341-350. doi: 10.1007/ s11060-008-9669-3.
6. DeAngelis LM: Brain tumors. N Engl J Med. 2001, 344:114-123. doi: 10.1056/NEJM200101113440207.
7. Shaw EG, ScheithauAr BW, O'Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol. 1997, 31:273-278. doi: 10.1023/A:1005715703598.
8. Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients. J Clin Oncol. 1997, 15:3129-3140.
9. Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 2008, 26: 2008 (May 20 suppl; abstr 2006)
10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002, 20:2076-2084. doi: 10.1200/JCO.2002.08.121.
11. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY: Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 2005, 78:230-235. doi: 10.1259/bjr/28534346.
12. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM: Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008, 109:817-824. doi: 10.3171/JNS/2008/109/11/0817.
13. Schiff D, Brown PD, Giannini T: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007, 69:1366-1373. doi: 10.1212/01.wnl.0000277271.47601.a1.
14. Ricci PE, Dungan DH: Imaging of low- and intermediate-grade gliomas. Semin Radiat Oncol 2001, 11:103-112. doi: 10.1053/srao.2001.21420.
15. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, Morioka T, Fukui M, Masuda K: A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998, 25:1261-1269. doi: 10.1007/s002590050294.
16. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996, 78:1107-1113. doi: 10.1002/ (SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5.
17. Torp SH, Alsaker M: Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 2002, 198:261-265.
18. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006, 66:9852-9861. doi: 10.1158/0008-5472.CAN-06-1796.
19. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology. 2005, 25:1-7. doi: 10.1111/j.1440-1789.2004.00600.x.
20. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J: MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006, 60:740-743. doi: 10.1002/ana.21044.
21. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendroRliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006, 106:1759-1765. doi: 10.1002/cncr.21809.
22. Recht LD, Lew R, SmithITW: Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992, 31:431-436. doi: 10.1002/ana.410310413.
23. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M: Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial. J Neurosurg. 2008, 109:835-841. doi: 10.3171/JNS/2008/109/11/0835.
24. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: A critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001, 95:735-745.
25. Sanai N, Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62:753-764. doi: 10.1227/ 01.neu.0000318159.21731.cf.
26. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008, 26:1338-1345. doi: 10.1200/JCO.2007.13.9337.
27. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH: Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994, 34:577-582. doi: 10.1097/00006123-199404000-00002.
28. Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, Abe M: Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer 1993, 72:190-195. doi: 10.1002/ 1097-0142(19930701)72:1<190::AID-CNCR2820720134>3.0.CO;2-Y.
29. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van GM: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: An interim analysis. Int J Radiat Oncol Biol Phys. 2002, 52:316-324. doi: 10.1016/S0360-3016(01)02692-X.
30. van den Bent MJ, Afra D, De Witte O, Ben HM, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005, 366:985-990. doi: 10.1016/S0140-6736(05)67070-5.
31. Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R: Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 1994, 73:1937-1945. doi: 10.1002/ 1097-0142(19940401)73:7<1937::AID-CNCR2820730727>3.0.CO;2-G.
32. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF: Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993, 32:554-559. doi: 10.1097/00006123-199304000-00010.
33. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002, 20:2267-2276. doi: 10.1200/JCO.2002.09.126.
34. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996, 36:549-556. doi: 10.1016/S0360-3016(96)00352-5.
35. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, al-Sarraf M: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group study. J Neurosurg. 1993, 78:909-914.
36. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM: Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol. 2003, 14:1722-1726. doi: 10.1093/annonc/mdg502.
37. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003, 21:646-651. doi: 10.1200/ JCO.2003.01.009.
38. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066-1073. doi: 10.1097/00006123-199811000-00035.
39. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005, 103:802-809. doi: 10.1002/cncr.20828.
40. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203-207.
41. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007, 14:391-398. doi: 10.1111/j.1468-1331.2007.01675.x.
42. Buckner JC, Gesme D, Jr., O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003, 21:251-255. doi: 10.1200/ JCO.2003.06.023.
43. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003, 14:599-602. doi: 10.1093/annonc/mdg157.
44. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht C, Allgeier A, Gorlia T: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003, 21:2525-2528. doi: 10.1200/JCO.2003.12.015.
45. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998, 90: 1473-1479. doi: 10.1093/jnci/90.19.1473.
46. Jenkins RB, Curran W, Scott CB, Cairncross G: Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol. 2001, 24:506-508. doi: 10.1097/00000421-200110000-00018.
47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-996. doi: 10.1056/ NEJMoa043330.
48. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003, 14:1715-1721. doi: 10.1093/annonc/mdg371.
49. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004, 22:3133-3138. doi: 10.1200/JCO.2004.10.169.
50. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K: Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 2007, 68:1831-1836. doi: 10.1212/01.wnl.0000262034.26310.a2.
51. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, Dzik-Jurasz AS: Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004, 90:781-786. doi: 10.1038/sj.bjc.6601593.
52. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D: Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007, 82:281-288. doi: 10.1007/ s11060-006-9280-4.
53. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260. doi: 10.1212/01.wnl.0000208958.29600.87.
54. Pediatric Brain Tumor Consortium and National Cancer Institute (NCI): Bevacizumab and irinotecan in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma. http://clinicaltrials.gov, 2009. Accessed February 27, 2009
55. Savage DG, Antman KH: Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002, 346:683-693. doi: 10.1056/NEJMra013339.
56. Duke University and Novartis Pharmaceuticals: Phase II imatinib + hydroxyurea in treatment of patients with recurrent/progressive grade II low-grade glioma (LGG). http://clinicaltrials.gov, 2009. Accessed February 27, 2009
57. UCSF Helen Diller Family Comprehensive Cancer Center and National Cancer Institute (NCI): Everolimus in treating patients with recurrent or progressive low-grade glioma. http://clinicaltrials.gov, 2009. Accessed February 27, 2009